19-1398994-GC-GCC
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PP4_StrongPM2_SupportingPVS1_StrongPM3_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000156.6:c.491dup (p.Val165ArgfsTer26) variant in GAMT is a frameshift variant predicted to cause a premature stop codon in the last 50 nucleotides of the penultimate exon of the gene and therefore to escape nonsense mediated decay. More than 10% of the protein is predicted to be removed (PVS1_Strong; PMID:11136556). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001 in the East Asian population, which is less than the ClinGen CCDS VCEP's threshold (<0.0004) (PM2_Supporting). The variant was found in homozygosity in one patient who meets the ClinGen CCDS VCEP's PP4 specifications (PMID 12557293). This variant was also found in compound heterozygosity in two patients who meet ClinGen CCDS VCEP’s PP4 specifications; one with the variant c.564G>T (p. Met188Ile) (PMID 28438604) or "IVS5-3C>G" (PMID 11136556). However, the in trans data from these two patients will be used in the assessment of the second variant and is not included here to avoid circular logic. (PM3_Supporting). Three patients have been reported with this variant and clinical and biochemical features consistent with GAMT deficiency including an adult patient with low creatine and elevated GAA in urine, plasma, and CSF, <10% normal GAMT activity in fibroblasts, and absent creatine peak with GAA detected on MRS (PMID 12557293), low creatine and elevated GAA in plasma and urine and absent creatine peak on MRS (PMID 28438604), and elevated GAA in plasma, urine, and CSF, and lacking creatine peak on brain MRS (PMID 1136556)(PP4_Strong). There is a ClinVar entry for this variant (Variation ID: 495685) In summary, this variant meets the criteria to be classified as Pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PVS1_Strong, PP4_Strong, PM2_Supporting, PM3_Supporting.(Classification approved by the ClinGen CCDS VCEP on June 6, 2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CA9043628/MONDO:0012999/026
Frequency
Consequence
NM_000156.6 frameshift
Scores
Clinical Significance
Conservation
Publications
- guanidinoacetate methyltransferase deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet, G2P, ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000156.6. You can select a different transcript below to see updated ACMG assignments.
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAMT | TSL:1 MANE Select | c.491dupG | p.Val165ArgfsTer26 | frameshift | Exon 5 of 6 | ENSP00000252288.1 | Q14353-1 | ||
| GAMT | c.761dupG | p.Val255ArgfsTer26 | frameshift | Exon 5 of 6 | ENSP00000572533.1 | ||||
| GAMT | TSL:2 | c.491dupG | p.Val165ArgfsTer26 | frameshift | Exon 5 of 5 | ENSP00000403536.2 | Q14353-2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000239 AC: 6AN: 250692 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.0000178 AC: 26AN: 1461116Hom.: 0 Cov.: 33 AF XY: 0.0000151 AC XY: 11AN XY: 726862 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74352 show subpopulations
Age Distribution
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at